Immunoglobulin (Ig) G1 antibodies stimulate antibody-dependent cell-mediated cytotoxicity
(ADCC). Cetuximab, an IgG1 isotype monoclonal antibody, is a standard-of-care treatment …

Natural killer (NK) cells are central components of the innate immunity. In murine models, it
has been shown that NK cells can control both local tumor growth and metastasis due to …

Purpose To evaluate the efficacy of cetuximab plus taxane/carboplatin (TC) as first-line
treatment of advanced non–small-cell lung cancer (NSCLC). Patients and Methods This …

Despite recent molecular and immunological advancements, prognosis of metastatic
colorectal cancer (mCRC) patients remains poor. In this context, several retrospective and …

Background Cardiotoxicity is a major complication of anticancer drugs, including
anthracyclines and 5-fluorouracil (5-FU) and it can have detrimental effects both in patients …

Purpose To investigate the effect of adding concurrent chemotherapy (CT) to cetuximab plus
radiotherapy (RT; CT-cetux-RT) compared with cetuximab plus RT (cetux-RT) in locally …

In the era of personalized medicine, high-throughput technologies have allowed the
investigation of genetic variations underlying the inter-individual variability in drug …

Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and
panitumumab is the main targeted treatment to combine with standard chemotherapy for …

Introduction N-glycosylation is a post-translational modification that is highly important for
the development of monoclonal antibodies (mAbs), as it regulates their biological activity …

Purpose: In a recent randomized phase III clinical trial in metastatic colorectal cancer
patients, the addition of the anti-epidermal growth factor receptor (EGFR) monoclonal …